Jack Nathan Medical AI Stock Analysis
Want to see TSE:JNH full AI Analyst Report?
Jack Nathan Medical (JNH) AI Stock Analysis
Jack Nathan Medical
(TSXV:JNH)
Jack Nathan Medical's overall stock score of 40 reflects significant challenges, primarily driven by poor financial performance with a steep revenue decline, negative cash flows, and weak profitability. Technical analysis indicates limited momentum and high volatility, while valuation metrics highlight unprofitability with a negative P/E ratio. Investors should approach with caution due to these substantial risks.
Jack Nathan Medical (JNH) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 87.10K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.16
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 24
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Jack Nathan Medical Business Overview & Revenue Model
Company Description
Jack Nathan Medical Corp. (JNH.V), along with its affiliated entities, primarily delivers primary healthcare services under the Jack Nathan Health brand. These medical clinics are predominantly located within Walmart Supercentres. As of June 30, 2022...
How the Company Makes Money
Jack Nathan Medical generates revenue primarily through the provision of healthcare services to patients who visit its clinics. The company bills provincial health insurance plans for covered services, which constitutes a significant portion of its r...
Jack Nathan Medical Financial Statement Overview
Summary
Jack Nathan Medical's financial performance is weak, with a sharp 59.18% revenue decline, persistent negative cash flows (-$6.37M operating, -$7.54M free cash flow), and negative margins (EBIT -28.48%). While equity improved to $1.32M and gross margin remains strong at 84.65%, the overall financial health signals significant operational challenges and limited growth capacity.
Income Statement
35NegativeBalance Sheet
40NegativeCash Flow
30Negative| Breakdown | TTM | Apr 2025 | Jan 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.62M | 8.71M | 19.14M | 15.49M | 9.64M | 3.85M |
| Gross Profit | 7.27M | 7.37M | 14.48M | 11.82M | 6.92M | 3.74M |
| EBITDA | -1.73M | -1.29M | -4.96M | -5.51M | -7.54M | -10.11M |
| Net Income | 7.09M | 7.46M | -6.64M | -7.08M | -7.81M | -9.90M |
Balance Sheet | ||||||
| Total Assets | 2.65M | 3.54M | 11.19M | 6.45M | 10.65M | 406.78K |
| Cash, Cash Equivalents and Short-Term Investments | 906.49K | 2.20M | 3.07M | 1.46M | 7.69M | 406.78K |
| Total Debt | 224.69K | 243.31K | 12.39M | 4.55M | 713.02K | 713.02K |
| Total Liabilities | 2.45M | 2.22M | 17.13M | 8.32M | 2.13M | 17.18K |
| Stockholders Equity | 203.43K | 1.32M | -5.95M | -1.87M | 8.53M | 389.59K |
Cash Flow | ||||||
| Free Cash Flow | -6.19M | -7.54M | -10.20M | -4.59M | -1.31M | -566.27K |
| Operating Cash Flow | -5.47M | -6.36M | -6.11M | -2.00M | -809.16K | -66.53K |
| Investing Cash Flow | 4.90M | 4.45M | -4.09M | -2.69M | -252.89K | -252.89K |
| Financing Cash Flow | -177.35K | 1.04M | 11.91M | 5.28M | 8.68M | 389.11K |
Jack Nathan Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:JNH, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of -0.00 indicates Neutral momentum. The RSI at is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:JNH.
Jack Nathan Medical Peers Comparison
Overall Rating
TSE:NLH71Outperform
TSE:CRRX63Neutral
TSE:WELL57Neutral- TSE:JNH40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:NLH | 71Outperform | CAD 43.66M | 21.68 | 6.95% | ― | 15.57% | 65.83% |
| TSE:CRRX | 63Neutral | CAD 201.17M | 7.79 | 23.35% | 2.62% | 3.42% | 40560.00% |
| TSE:WELL | 57Neutral | CAD 954.68M | -7.72 | -15.34% | ― | 29.14% | -189.23% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:JNH | 40Underperform | CAD 413.49K | -0.10 | -322.95% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:JNH | Jack Nathan Medical Corp | 0.01 | 0.00 | 0.00% | |
| TSE:CRRX | Carerx Corporation | 3.13 | -0.22 | -6.57% | |
| TSE:NLH | Nova Leap Health | 0.48 | 0.18 | 61.67% | |
| TSE:WELL | Well Health Technologies | 3.79 | -0.29 | -7.11% | |
| TSE:CALM | Revitalist Lifestyle & Wellness Ltd. | 0.02 | 0.00 | 0.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 11, 2025